Novavax (NVAX) Accounts Payables (2010 - 2026)
Novavax (NVAX) posted quarterly Accounts Payables of $16.1 million for Q1 2026, down 52.87% year-over-year from $34.2 million in Q1 2025, and down 34.49% quarter-over-quarter from $24.6 million in Q4 2025.
Novavax (NVAX) Accounts Payables (2010 - 2026) Analysis & Trends
Novavax's Accounts Payables history runs 17 years deep, the most recent figure standing at $16.1 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 52.87% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (down 52.87% YoY), while the FY2025 annual figure was $24.6 million, down 40.89% from the prior year.
- Accounts Payables for Q1 2026 stood at $16.1 million, down from $24.6 million in the prior quarter.
- The five-year high for Accounts Payables was $386.5 million in Q2 2022, with the low at $15.2 million in Q3 2025.
- The 5-year median for Accounts Payables is $80.0 million (2024), against an average of $100.4 million.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 422.32% in 2022, then sank 77.43% in 2023.
- Novavax's Accounts Payables stood at $216.5 million in 2022, then plunged by 38.75% to $132.6 million in 2023, then tumbled by 68.65% to $41.6 million in 2024, then sank by 40.89% to $24.6 million in 2025, then plunged by 34.49% to $16.1 million in 2026.
- Business Quant data shows NVAX's Accounts Payables at $16.1 million in Q1 2026, $24.6 million in Q4 2025, and $15.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 22.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.94 Mn |
| Mar 31, 2026 | 16.10 Mn |
| Dec 31, 2025 | 24.58 Mn |
| Sep 30, 2025 | 15.23 Mn |
| Jun 30, 2025 | 50.60 Mn |
| Mar 31, 2025 | 34.16 Mn |
| Dec 31, 2024 | 41.58 Mn |
| Sep 30, 2024 | 57.52 Mn |
| Jun 30, 2024 | 79.96 Mn |
| Mar 31, 2024 | 57.72 Mn |
| Dec 31, 2023 | 132.61 Mn |
| Sep 30, 2023 | 101.91 Mn |
| Jun 30, 2023 | 87.25 Mn |
| Mar 31, 2023 | 124.80 Mn |
| Dec 31, 2022 | 216.52 Mn |
| Sep 30, 2022 | 145.00 Mn |
| Jun 30, 2022 | 386.49 Mn |
| Mar 31, 2022 | 135.13 Mn |
| Dec 31, 2021 | 127.05 Mn |
| Sep 30, 2021 | 59.56 Mn |